Dr. Xin W. Wang Wins 2021 Blue Faery Award
As a Senior Investigator at the National Cancer Institute (NCI), Dr. Wang has dedicated his professional life to improving early detection, diagnosis and treatment of liver cancer for over 25 years. He is also co-Director of the Multidisciplinary CCR Liver Cancer Program, Deputy Lab Chief of the CCR Laboratory of Human Carcinogenesis and co-PI of the CCR Liver Moonshot CLARITY. Dr. Wang applies genome-scale technologies paired with several international collaborative initiatives and clinical studies. He has co-authored over 200 scientific articles including a recent study published in Cell.
Upon receiving the BFA Dr. Wang stated, “I am so thrilled to hear this wonderful news. It's an absolute honor to receive this year's award, especially in the midst of the COVID-19 pandemic and as the recipient who has ever won this award twice. Thanks to the board for recognizing our works.”
See previous Blue Faery Award Winners here.
Dr. Ann-Lii Cheng Wins 2020 Blue Faery Award
Professor Ann-Lii Cheng has contributed significantly to the basic knowledge and clinical application of molecular targeted therapy and immunotherapy in hepatocellular carcinoma (HCC). Living in the part of the world plagued by HCC, Prof. Cheng has devoted his career to substantiating a solution. Since 2004, he has been involved in the development of sorafenib and lenvatinib, two pivotal drugs in the first-line treatment of HCC, and recently the discovery of a new regimen, atezolizumab plus bevacizumab, which is considered an epoch-making breakthrough in this field. His research team at National Taiwan University has been recognized as one of the most prominent translational research groups in exploring the frontier of HCC treatment.
Dr. Jinsil Seong Wins 2019 Blue Faery Award
Professor Seong is one of a few who pioneered radiotherapy of Hepatocellular Carcinoma. She has devoted her entire career on radiotherapy of HCC by practicing, educating and pursuing clinical research. With her enthusiasm and devotion overcoming a minority issue not only in specialty (radiation oncology) but also in gender (women), she has served as a president of the Korean Liver Cancer Association. Additionally, she is the president-elect of the Asia Pacific Primary Liver cancer Expert (APPLE) association, which is a world leading liver cancer association.